Enlivex Therapeutics Ltd.
TTASE:ENLVShare Statistics
As of December 31, 2025, Enlivex Therapeutics Ltd. has 237.38M shares outstanding.
| Shares Outstanding | 237.38M |
Valuation Ratios
As of December 31, 2025, Enlivex Therapeutics Ltd. trades at a trailing price-to-earnings ratio of 1.30.
| PE Ratio | 1.30 |
| PB Ratio | 1.41 |
| P/TBV Ratio | 0.83 |
| P/FCF Ratio | -155.17 |
| P/OCF Ratio | -154.16 |
Financial Position
As of December 31, 2025, Enlivex Therapeutics Ltd. maintains a current ratio of 193.24, meaning it holds 193.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 193.24 |
| Quick Ratio | 0.69 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.04 |
Financial Efficiency
These figures cover the twelve months ended December 31, 2025. Return on invested capital (ROIC) is negative at -1.53, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 104.94, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 243.72, useful for judging operating efficiency across full business cycles.
| Return on Assets (ROA) | 104.94 |
| Return on Invested Capital (ROIC) | -1.53 |
| Return on Capital Employed (ROCE) | 243.72 |
Dividends & Yields
These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -0.64: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.65, meaning Enlivex Therapeutics Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -0.65 |
| FCF Yield | -0.64 |
Scores
As of December 31, 2025, Enlivex Therapeutics Ltd. has an Altman Z-Score of 4.00, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.00 |